20/20 Onsite is a mobile vision‑care company that operates a fleet of certified mobile eye clinics delivering on‑site and hybrid clinical‑trial eye assessments, workplace and school vision services, and related optical care nationwide. [1][3]
High‑Level Overview
- 20/20 Onsite’s core offering is mobile vision care delivered through purpose‑built Mobile Vision Clinics that perform both routine eye care and clinical‑trial‑grade ophthalmic testing, now certified for site readiness by Precision Vision’s Clinical Trial Solutions team.[1][3]
- Who it serves: employers, schools, health plans, CROs and biopharma sponsors, and patients who need point‑of‑need vision services or access to clinical trials outside traditional clinic locations.[1][3]
- Problem solved: reduces geographic, logistic and access barriers to eye care and ophthalmic clinical trial participation by bringing high‑quality testing (e.g., BCVA/ETDRS) and controllable test environments to patients at workplaces, schools, and community locations.[1]
- Growth momentum: founded in 2014 and recognized among fast‑growing companies (Inc. list); by 2023 it had expanded into life‑sciences trial support and earned multiple industry certifications while raising growth capital to expand its fleet and clinical‑trial capabilities.[1][3]
Origin Story
- Founding and early focus: 20/20 Onsite was founded in 2014 and launched its first mobile vision center in Boston to provide on‑site vision services to employers and communities.[3]
- Evolution into life‑sciences support: in May 2020 the company expanded services to support biopharma companies and CROs, adapting its mobile clinics to perform trial assessments and ramping clinical capabilities thereafter.[1]
- Early traction and funding: the company has been named an Inc. Fastest‑Growing Company and completed growth financing rounds (sources report an $8M round and later tranches) to scale operations and bolster clinical trial offerings.[1][3]
Core Differentiators
- Clinical trial‑ready mobile units: first mobile clinic to earn a Site Readiness Certification from Precision Vision Clinical Trial Solutions, demonstrating the ability to meet strict BCVA/ETDRS testing requirements and controllable lighting conditions aboard the vehicle.[1]
- Certifications and quality standards: additional ophthalmic and air‑quality certifications (Emmes Optym, STERIS) that signal readiness for regulated clinical assessments.[1]
- Point‑of‑need delivery model: purpose‑built vehicles staffed by trained clinical teams that reduce participant burden and expand geographic reach for routine eye care and trial enrollment.[1][3]
- Dual market focus: services for commercial eye care (employers/schools) and life‑sciences customers (CROs/bioPharma), enabling diversified revenue streams and cross‑leveraging operational capabilities.[1][3]
Role in the Broader Tech and Health Landscape
- Trend alignment: rides two converging trends—healthcare decentralization (mobile and hybrid care delivery) and decentralized clinical trials—by enabling regulated ophthalmic testing outside brick‑and‑mortar sites.[1]
- Timing and market forces: increasing pressure to improve clinical trial diversity, reduce participant burden, and reach underserved populations creates demand for mobile, site‑agnostic assessment solutions that maintain data quality.[1]
- Ecosystem influence: by certifying mobile clinics to clinical‑trial standards, 20/20 Onsite helps validate mobile modalities for regulated endpoints and may lower barriers for sponsors to adopt decentralized eye‑care assessments.[1]
Quick Take & Future Outlook
- Near term: expect continued fleet and service expansion for both employer/school programs and life‑sciences trial support, backed by prior growth capital and certification milestones that position the company as a preferred mobile ophthalmic partner for sponsors.[1][3]
- Mid term trends to watch: broader adoption of decentralized clinical trials, payer and employer interest in on‑site preventive care, and potential technology integrations (remote testing, tele‑ophthalmology) that could deepen service offerings. [1][3]
- How influence may evolve: if 20/20 Onsite sustains certification, data quality, and scale, it could become a standard operational layer for ophthalmic endpoints in decentralized trials and a leading vendor for employer‑based vision programs, tying back to its original mission of expanding access to high‑quality vision care.[1][3]
